<code id='FD0DF7D970'></code><style id='FD0DF7D970'></style>
    • <acronym id='FD0DF7D970'></acronym>
      <center id='FD0DF7D970'><center id='FD0DF7D970'><tfoot id='FD0DF7D970'></tfoot></center><abbr id='FD0DF7D970'><dir id='FD0DF7D970'><tfoot id='FD0DF7D970'></tfoot><noframes id='FD0DF7D970'>

    • <optgroup id='FD0DF7D970'><strike id='FD0DF7D970'><sup id='FD0DF7D970'></sup></strike><code id='FD0DF7D970'></code></optgroup>
        1. <b id='FD0DF7D970'><label id='FD0DF7D970'><select id='FD0DF7D970'><dt id='FD0DF7D970'><span id='FD0DF7D970'></span></dt></select></label></b><u id='FD0DF7D970'></u>
          <i id='FD0DF7D970'><strike id='FD0DF7D970'><tt id='FD0DF7D970'><pre id='FD0DF7D970'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:6659
          Two Vertex buidings in the Seaport District
          David L Ryan/Globe Staff

          When Vertex Pharmaceuticals moved from Cambridge to Boston’s Seaport a decade ago, it signaled that what was then a sea of parking lots could be a booming business district, and galvanized a wave of new development.

          Now, Vertex may be on the move again.

          advertisement

          With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          GSK to buy asthma
          GSK to buy asthma

          AdobeLONDON—GSKsaidTuesdayitwouldpurchasetheasthma-focuseddrugdeveloperAiolosBiofor$1billionupfront,

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S